Cell line development is a critical upstream step for the manufacture of monoclonal antibodies (MAbs). Cells must be engineered to produce a biologic of interest, and the right clone must be selected to deliver material for preclinical and clinical studies. A high-producing cell line is then needed to support clinical studies and, ultimately, commercialization of the therapeutic.

Please fill out the form below to read more.

Corresponding authors are Aurore Poles, Global Technical and Compliance Expert, and Guillaume Plane, Global Development and Marketing Manager; aurore.poles@milliporesigma.com and guillaume.plane@milliporesigma.com. Both focus on BioReliance® End-to-End Solutions at MilliporeSigma.

The life science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the United States and Canada.

To learn about our plug-and-play upstream development service, please visit EMDMillipore.com/plug-play-upstream.